The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug ...

Eli Lilly launches diabetes and obesity drug Mounjaro in India, offering innovative treatment for metabolic health management ...

TiumBio (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative ...

Benchmark NSE Nifty50 index ended up 283.06 points at 23190.65, while the BSE Sensex stood up 899.01 points at 76348.06.

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

India 10-year bond yield fell 0.41 per cent to 5.89 after trading in 5.87-5.91 range NEW DELHI: The Nifty Pharma index traded ...

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

Based on the reciprocal tariff approach, a 10% tariff on Indian pharma imports could be a possibility, but BofA cites a few ...

The respiratory segment, often influenced by seasonal factors, registered a 1.1% increase in value but faced a 4.6% decline ...

With artificial photosynthesis, mankind could utilize solar energy to bind carbon dioxide and produce hydrogen. Chemists from ...

Mankind Pharma launches affordable empagliflozin in India for diabetes: Our Bureau, Mumbai Thursday, March 13, 2025, 17:30 Hrs [IST] Mankind Pharma has launched its affordable gen ...